Allopathy
Prescription Required
DCGI (Drugs Controller General of India)
Schedule H
Magaldrate is an Antacid belonging to a Gastric acid neutralizer.
Magaldrate is an antacid used to treat various conditions in the GI tract, such as esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux.
Magaldrate shows side effects like Constipation, Diarrhea, Chalky taste, Stomach cramps, Nausea and Vomiting.
Magaldrate is available in the form of Oral Suspension.
Magaldrate is available in India, Bangladesh, Nigeria, China, Japan, and Germany.
Magaldrate belongs to the Gastric acid neutralizer and acts as an Antacid.
Mechanism of Action of Magaldrate antacid that causes less hydrogen ion available for diffusion through the gastrointestinal (GI) mucosa which reduces and neutralizes gastric acid.
The onset of action of Magaldrate can be observed within 20 minutes of administration of the dose.
The duration of action of Magaldrate remains effective and is subject to vary based on the gastric emptying time. In the fasting state, it is effective for approximately 20-60 minutes and if taken 1 hour after the meals. it is effective for up to 3 hours.
Magaldrate is available in the form of Oral Suspension.
Magaldrate suspension is taken orally, usually in a divided doses.
Magaldrate is a complex of aluminum and magnesium that is used to relieve heartburn, sour stomach, acid ingestion, upset stomach, etc.
Magaldrate is an Antacid belonging to a Gastric acid neutralizer.
Mechanism of Action of Magaldrate antacid that causes less hydrogen ion available for diffusion through the gastrointestinal (GI) mucosa which reduces and neutralizes gastric acid.
Magaldrate is approved for use in the following clinical indications
- Heartburn, Sour Stomach, and Acid Indigestion
- Hyperphosphatemia, magnesium deficiency
- Off-label: Gastric and duodenal ulcer, GERD
- Neutralizes gastric acid, and increases gastric pH.
- Heartburn, Sour Stomach, and Acid Indigestion
5-10 mL (1-2 teaspoonfuls; 540-1080 mg) between meals and at bedtime; not to exceed 80 mL (16 teaspoonfuls) in a 24-hour period.
Magaldrate is available in various strengths as 540 mg/5 mL.
Magaldrate is available in the form of Oral Suspension.
Magaldrate is contraindicated in patients with
- Allergy
Magaldrate is not recommended for use in patients with a known allergy to aluminum hydroxide, magnesium hydroxide, or any other inactive ingredients present along with them.
- Severe renal impairment
Magaldrate is not recommended for use in patients suffering from severe impairment of kidney function due to the increased risk of worsening of the patient's condition.
- Hypermagnesemia
The use of Magaldrate may increase the magnesium levels in the blood. The risk is especially higher in patients suffering from kidney diseases. Report any symptoms such as flushing of the skin, increased thirst, difficulty in breathing, changes in heart rate, etc. to the doctor immediately. Close monitoring of magnesium levels, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
- Kidney diseases
Magaldrate should be used with caution in patients suffering from kidney diseases due to the increased risk of severe adverse effects. Close monitoring of kidney function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Alcohol Warning
Consumption of alcohol should be avoided.
Breast Feeding Warning
Magaldrate is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be considered before using Magaldrate.
Pregnancy Warning
Magaldrate is not recommended for use in pregnant women unless necessary. All the risks and benefits should be considered before using Magaldrate.
The common side effects of Magaldrate include the following
- Common side effects
Constipation, Diarrhea, Chalky taste, Stomach cramps, Nausea, and Vomiting.
- Pregnancy
Pregnancy Category
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be considered before using this medicine.
- Nursing Mothers
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be considered before using this medicine.
- Estruch R, Pedrol E, Castells A, Masanes F, Marrades RM, Urbano-Marquez A. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. Scandinavian Journal of gastroenterology. 1991 Jan 1;26(8):819-26.
- Giannini EG, Zentilin P, Dulbecco P, Iiritano E, Bilardi C, Savarino E, Mansi C, Savarino V. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Digestive diseases and sciences. 2006 Nov;51:1904-9.
- McCafferty DF, Woolfson AD. A comparative assessment of a new antacid formulation based on magaldrate. Journal of Clinical Pharmacy and Therapeutics. 1983 Aug;8(4):349-55.
- https://go.drugbank.com/drugs/DB08938
- https://www.drugs.com/sfx/magaldrate-side-effects.html
- https://reference.medscape.com/drug/mylanta-mygel-aluminum-hydroxide-magnesium-hydroxide-simethicone-341982
- https://www.practo.com/medicine-info/magaldrate-1826-api
- https://www.drugs.com/mtm/magaldrate.html#:~:text=What happens if I overdose,cramps, or other stomach problems.
